NCT06642545View on ClinicalTrials.gov

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2027

Conditions
Breast Cancer
Interventions
DRUG

Disitamab Vedotin

Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks

DRUG

RC148

20mg/kg, intravenous infusion, once every 2 weeks

DRUG

Albumin-bound Paclitaxone

125 mg/m2,intravenous infusion, D1-8, every 3 weeks

DRUG

Toripalimab

240mg,intravenous infusion, once every 3 weeks

Trial Locations (1)

Unknown

RECRUITING

Cance Hosoltal Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY